A randomized phase 2 I-SPY2 trial examined the efficacy of neoadjuvant treatment that included pembrolizumab, on participants with early-stage, high-risk, ERBB2 (formerly HER2)-negative breast cancer. Here, ERBB2 is linked to breast carcinoma.